International Clinical Trial: A Randomized, Controlled, Open-Label, Single-Center Clinical Trial of Aiplolitowrelizumab plus Lenvatinib as Adjuvant Therapy in Patients with High-Risk Recurrent Hepatocellular Carcinoma after TACE Followed by Thermal Ablation

Geneva, June 8 -- International Clinical Trials Registry received information related to the study (ChiCTR2600125756) titled 'A Randomized, Controlled, Open-Label, Single-Center Clinical Trial of Aiplolitowrelizumab plus Lenvatinib as Adjuvant Therapy in Patients with High-Risk Recurrent Hepatocellular Carcinoma after TACE Followed by Thermal Ablation' on May 31.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Beijing Youan Hospital, Capital Medical University

Condition: Hepatocellular Carcinoma

Intervention: experimental group:To receive aiplolitowrelizumab combined with lenvatinib as adjuvant therapy starting 3 to 7 days after TACE sequential thermal ablation.

Recruitment Status: Not Recruiting

Phase:...